Zbtb7a has previously been described as a powerful proto-oncogene. Here we unexpectedly demonstrate that Zbtb7a has a critical oncosuppressive role in the prostate. Prostate-specific inactivation of Zbtb7a leads to a marked acceleration of Pten loss-driven prostate tumorigenesis through bypass of Pten loss-induced cellular senescence (PICS). We show that ZBTB7A physically interacts with SOX9 and functionally antagonizes its transcriptional activity on key target genes such as MIA, which is involved in tumor cell invasion, and H19, a long noncoding RNA precursor for an RB-targeting microRNA. Inactivation of Zbtb7a in vivo leads to Rb downregulation, PICS bypass and invasive prostate cancer. Notably, we found that ZBTB7A is genetically lost, as well as downregulated at both the mRNA and protein levels, in a subset of human advanced prostate cancers. Thus, we identify ZBTB7A as a context-dependent cancer gene that can act as an oncogene in some contexts but also has oncosuppressive-like activity in PTen-null tumors.
ZBTB7A (also known as LRF, Pokemon, FBI-1 and OCZF) is a member of the POK (POZ/BTB and Krüppel) transcription factor family [1] [2] [3] [4] that has important roles in cellular differentiation and oncogenesis [5] [6] [7] [8] [9] . We have previously shown that ZBTB7A is highly expressed in non-Hodgkin lymphoma tissues and acts as a proto-oncogene through its ability to directly repress the expression of the tumor suppressor ARF 1 . Recently, overexpression of ZBTB7A has been described in different types of human cancers of various origins, such as non-smallcell lung cancer (NSCLC), breast cancer and ovarian cancer [10] [11] [12] [13] [14] , reinforcing the role of ZBTB7A as an important proto-oncogene in multiple tissues.
Here we showed that Zbtb7a inactivation profoundly promotes the progression of Pten loss-driven prostate tumorigenesis by activating Sox9-dependent oncogenic pathways to bypass PICS and promote proliferation, survival and invasion. Notably, expression of ZBTB7A is lost in a subset of human advanced prostate cancers. Thus, these results suggest a context-dependent role for ZBTB7A in tumorigenesis.
RESULTS

Zbtb7a loss promotes Pten null-driven prostate tumorigenesis
To assess the possible proto-oncogenic role of ZBTB7A in prostate cancer development, we generated a transgenic mouse with prostatespecific overexpression of ZBTB7A. Unexpectedly, we found that overexpression of ZBTB7A in the prostate epithelium was insufficient to trigger any sign of neoplastic transformation (Supplementary Fig. 1) . At the same time, we also generated mice with conditional inactivation of Zbtb7a in the prostate (following a strategy described previously 15 ), expecting the mice to show profound suppression of tumor development when crossed with mice harboring genetic deletion of known prostate tumor suppressors such as Pten. Specifically, we crossed Pbsn-cre4 transgenic mice (expressing Cre after puberty in the prostate epithelium 16 ) with Zbtb7a fl/fl , Pten fl/fl or Pten fl/fl ; Zbtb7a fl/fl mice to conditionally inactivate Zbtb7a and Pten in the prostate (generating Pbsn-cre4; Zbtb7a fl/fl , Pbsn-cre4; Pten fl/fl and Pbsn-cre4; Pten fl/fl ; Zbtb7a fl/fl mutant mice). Inactivation of Zbtb7a alone in the Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion A r t i c l e s prostate did not lead to pathological changes in any prostate lobe in 11-week-old mice (n = 10 mice) ( Fig. 1a) . However, histopathological analysis using hematoxylin and eosin (Fig. 1a, top) , pan-cytokeratin ( Fig. 1a , middle) and smooth muscle actin (SMA) (Fig. 1a, bottom) staining showed unexpected, highly penetrant invasive prostatic adenocarcinoma at as early as 11 weeks in the mutants with inactivation of both Pten and Zbtb7a in the prostate. In line with our previous report 15 , at this age, only high-grade prostatic intraepithelial neoplasia (PIN) was found in the mice with inactivation of only Pten (n = 10) ( Fig. 1a,b) .
To further analyze the consequences of Zbtb7a inactivation for prostate cancer driven by Pten loss, we followed cohorts of mice with conditional inactivation of Pten alone and in combination with Zbtb7a by monthly magnetic resonance imaging (MRI) analysis. In agreement with previous reports 17 , MRI detected the presence of tumors in the prostates of 6-month-old mice with prostate-specific inactivation of Pten (Fig. 1c) . Tumors were significantly enlarged in the age-matched cohort that also had inactivation of Zbtb7a compared to tumors from mice with loss of Pten alone in terms of both tumor volume ( Fig. 1c,d) and weight ( Fig. 1e-g) .
To test whether the acceleration in prostate tumorigenesis described in the mice with inactivation of both Pten and Zbtb7a affected long-term survival, we followed a further cohort of mutant mice over 80 weeks. Kaplan-Meier cumulative survival analysis showed that concomitant loss of Zbtb7a and Pten led to lethal prostate tumors at around 13 months ( Fig. 1h-j) . Double-mutant mice with inactivation of both Pten and Zbtb7a either died or were euthanized owing to extensive tumor burden ( Fig. 1h,i) , whereas most mutant mice with inactivation of only Pten survived beyond 13 months ( Fig. 1j) . None of the wild-type control mice or those with prostate-specific inactivation of Zbtb7a alone died during this period, suggesting that loss of Zbtb7a in combination with Pten deficiency has a profound effect on the survival of the mutant mice. Thus, loss of Zbtb7a markedly accelerates the progression of prostate tumors driven by Pten loss, leading to massive tumor growth, early stromal invasion and lethal prostate cancer. To further define whether Zbtb7a had tumor suppressive-like functions in prostate cancer, we followed a cohort of wild-type mice and mutant mice with prostate-specific loss of Zbtb7a over a period of 2 years. We found that 16-to 18-month-old mutants with inactivation of Zbtb7a developed PIN in ventral and dorsolateral lobes (~17%; data not shown). Even though low disease penetrance affected the statistical power of this analysis, overall, these results suggest that inactivation of Zbtb7a can favor both tumor initiation and progression in prostate cancer. 
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Zbtb7a loss overcomes PICS and promotes tumor invasion
Next, we attempted to define the cellular and molecular mechanisms through which Zbtb7a suppress tumor formation in mice with prostatespecific inactivation of Pten. We had previously reported that PICS represents an important fail-safe mechanism for counteracting tumor progression in the prostate 15, 18 . We therefore tested the cellular senescence response in double-mutant mice with inactivation of both Pten and Zbtb7a in the prostate. To this end, prostate sections with various genotypes were analyzed by senescence-associated β-galactosidase (SA-β-gal) staining. A strong cellular senescence response was observed in mice with inactivation of Pten alone yet was markedly reduced in the double-mutant mice with inactivation of both Pten and Zbtb7a ( Fig. 2a ), suggesting that loss of Zbtb7a in a Pten-null context can yield an unexpected bypass of the senescence response ( Fig. 2b) .
We then investigated the mechanisms that could explain this unexpected senescence bypass. Along with other laboratories, we have previously demonstrated that the PICS program in the prostate is dependent on induction of p53, p27 and Smad4 (refs. 15,19,20) . We therefore compared the expression of these proteins in prostate tumors from mice with prostate-specific inactivation of Pten alone or double-mutant mice with inactivation of both Pten and Zbtb7a. Immunohistochemistry and protein blot analyses showed that p53, p27 and Smad4 protein amounts were similarly induced in Pten and Zbtb7a double-mutant and in single-mutant mice with loss of only Pten (Fig. 2c,d) . Furthermore, to ensure that the ability of p53 to regulate its downstream target genes was not impaired in the Pten and Zbtb7a double-mutant mice, we performed quantitative PCR (qPCR) analysis of Cdkn1a and Mdm2 mRNA levels as readout for p53 activity. Similar induction of both transcripts was observed in mice with inactivation of both Pten and Zbtb7a and in those with inactivation of only Pten (Supplementary Fig. 2a,b ), suggesting that p53 function was intact in the prostates of double-mutant mice and that evasion of the cellular senescence response in these mutants was attributable to a distinct cellular pathway. Additionally, in agreement with the previously reported role of ZBTB7A in ARF transcriptional repression 1 , we did observe an induction of Arf in Zbtb7a and Pten double-null mouse embryonic fibroblasts (MEFs) (Supplementary Fig. 2c ) and mouse prostates compared to their Pten-null counterparts ( Fig. 2c,d) . These findings are fully coherent with those of previous studies in which we proved genetically that the Arf transcript does not have a tumor-suppressive function in the mouse prostate on its own or, critical to this study, with concomitant loss of Pten 18, 21 . This notion has been further corroborated by our own as well as other investigators' previous analyses of human specimens, which have shown that complete loss of p14 ARF is extremely rare in human prostate cancer and that greater ARF abundance unexpectedly correlates with disease aggressiveness 21, 22 . The senescence bypass observed in Pten npg A r t i c l e s and Zbtb7a double mutants was also accompanied by a differential proliferation rate compared to the mutant with inactivation of Pten alone. There was a significant increase in the number of Ki-67positive prostate tumoral cells in the Pten and Zbtb7a double mutants compared to the mutants with loss of Pten alone ( Fig. 2e,f) , providing evidence that loss of Zbtb7a confers a proliferative advantage in the Ptendeficient prostate. In addition, protein blot analysis for cleaved caspase-3 showed that apoptosis in prostate tumors from Pten and Zbtb7a double mutants was substantially suppressed compared to mutants with inactivation of only Pten (Fig. 2g) . Thus, inactivation of Zbtb7a bypasses PICS, favoring proliferation, survival and invasion, even though p53, p27 and Smad are seemingly unaffected.
Zbtb7a deficiency promotes Sox9 oncogenic activity
We therefore hypothesized that Zbtb7a inactivation could transcriptionally perturb yet another pathway that promotes senescence, and we performed transcriptome analysis using prostates from 12-week-old wild-type mice and mice with prostate-specific inactivation of Zbtb7a
and Pten, alone and in combination (three mice per genotype). We found 567 genes whose expression was significantly upregulated and 482 genes whose expression was significantly downregulated by at least 1.5-fold (P < 0.01) in Pten and Zbtb7a double mutants compared to mutants with inactivation of only Pten ( Supplementary Table 1 ). Mia (encoding melanoma inhibitory activity) and Dmbt1 (encoding deleted in malignant brain tumors 1) were two of the most substantially upregulated genes in the ventral and anterior lobes of prostates from Pten and Zbtb7a double-mutant mice (Supplementary Fig. 3a) .
Notably, both genes are well-characterized transcriptional targets of Sry (sex-determining region Y)-box 9 (Sox9) [23] [24] [25] , although no increase in the levels of Sox9 mRNA was detected in mice with only Pten inactivation compared to those with inactivation of both Pten and Zbtb7a (Fig. 3a) . We additionally performed unbiased oPOSSUM analysis [26] [27] [28] , Ingenuity Pathway Analysis (IPA) and Gene Set Enrichment Analysis (GSEA) 29 the top ten transcription factors with over-represented binding sites in coexpressed genes (Supplementary Table 2) , an observation that is consistent with our hypothesis. In addition, by using two other independent bioinformatics tools, IPA and GSEA, we found that the most significantly enriched gene categories in the signature of mice with inactivation of both Pten and Zbtb7a were cellular movement, cell death and survival, and cellular growth and proliferation (Supplementary Tables 3 and 4) , a finding that is consistent with the aggressive nature of the prostate tumors in mice with this genotype that we observed by histopathological and molecular analyses (Figs. 1a,b and 2e,g) . Given that SOX9 has been shown to have important oncogenic functions in the prostate both in vitro and in vivo 31, 32 , we tested whether Sox9 and Zbtb7a functionally interact during prostate cancer development (Fig. 3) . We first performed qPCR analysis of Mia and Dmbt1 mRNAs to confirm the findings of the transcriptome analysis. Indeed, Mia and Dmbt1 mRNAs were highly upregulated in Pten and Zbtb7a double mutants compared to mice with inactivation of only Pten (Fig. 3a) . Because Sox9 expression is known to be markedly induced in Pten-deficient prostate 31 , we performed qPCR, protein blot and immunohistochemistry analyses to determine whether the concomitant loss of Zbtb7a and Pten affected Sox9 expression. Sox9 protein was expressed in both basal cells and luminal cells of the normal mouse prostate but was comparably induced in the mutant mice with loss of only Pten and double mutants with loss of both Pten and Zbtb7a (Fig. 3a,b,k) . On the basis of this observation, we hypothesized that the profound and differential increase in expression of Sox9 target genes observed in Pten and Zbtb7a double-null prostates was due to an increase in Sox9 transcriptional activity rather than its expression level.
ZBTB7A mainly acts as a transcriptional repressor 1 , whereas SOX9 mainly acts as a transcriptional activator 23 . We therefore tested whether ZBTB7A opposes the transcriptional activity of SOX9. To this end, we performed transactivation assays with a luciferase reporter construct containing multiple SOX9-binding sites 33 in PC3 and Du145 human prostate cancer cell lines that express low levels of endogenous ZBTB7A (Fig. 3c) . ZBTB7A efficiently abrogated the ability of SOX9 to transactivate the reporter gene in a dose-dependent manner in both cell lines ( Fig. 3d and Supplementary Fig. 3c ). Because the multimeric SOX9 reporter is an artificial responsive element devoid of ZBTB7A-binding sites, we next determined whether ZBTB7A repressed SOX9 transcriptional activity through direct physical interaction. To this end, we performed an immunoprecipitation assay in PC3 and RWPE-1 cells using an antibody to SOX9 and control immunoglobulin G (IgG). Antibody to SOX9 specifically pulled down endogenous ZBTB7A in both cell lines (Fig. 3e) , suggesting a physiological interaction between SOX9 and ZBTB7A in human prostate cells. Furthermore, immunoprecipitation using prostates from mice with inactivation of Pten that expressed high levels of both Zbtb7a and Sox9 also showed direct interaction of Zbtb7a and Sox9 in mouse primary prostate tumor cells ( Fig. 3e) .
To determine whether SOX9 target genes, such as MIA and DMBT1, were also regulated by ZBTB7A in human prostate cells, we inactivated ZBTB7A with a short hairpin RNA (shRNA) in RWPE-1 cells, which express high levels of endogenous ZBTB7A (Fig. 3c) . Subsequent qPCR analysis showed that MIA and DMBT1 mRNA levels were upregulated in cells in which ZBTB7A was inactivated compared to those transfected with the control shRNA (Fig. 3f) . Notably, chromatin immunoprecipitation (ChIP) assays with antibodies to ZBTB7A and SOX9 confirmed that both proteins specifically bound the promoters of MIA and DMBT1 (Fig. 3g) . These data demonstrate that MIA and DMBT1 are also SOX9 target genes in human prostate cells and that their expression depends on the relative amounts of ZBTB7A and SOX9.
Thus, the exacerbation of SOX9 oncogenic activities in prostate cancer as a consequence of ZBTB7A loss could drive hyperproliferation as well as enhance invasiveness through the activities of target genes such as MIA and DMBT1 (refs. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . On the basis of this idea, we speculated that Sox9 hyperactivity in Pten and Zbtb7a doublemutant mice might also be responsible for senescence bypass. With respect to this hypothesis, we noticed that the Sox9 target gene H19, which encodes a precursor noncoding RNA for the miR-675 micro-RNA (miRNA) 45 , was strongly upregulated in the double-mutant mice compared to those with inactivation of only Pten (Fig. 3h, left and  Supplementary Fig. 3a) . Given that miR-675 is known to target the tumor suppressor retinoblastoma (Rb) 46 , a key regulator of the cellular senescence response 47 , we tested whether miR-675 expression was concomitantly increased in Pten and Zbtb7a double-mutant mice. Indeed, expression levels of miR-675 were far higher in the prostates of the double-mutant mice than in mice with inactivation of Pten alone (Fig. 3h, right and Supplementary Fig. 4) . Accordingly, H19 mRNA was also strongly induced when ZBTB7A was transiently inactivated in human RWPE-1 cells (Fig. 3i) . Furthermore, both SOX9 and ZBTB7A were found to bind to the H19 promoter, as shown by ChIP assay (Fig. 3j) , suggesting that H19 is a direct target for both of these transcription factors in prostate cells. Protein blot and immunohistochemistry analyses confirmed that Rb protein expression was strongly downregulated in prostate tissue from Pten and Zbtb7a double-mutant mice (Fig. 3k,l) . As expected, lower amounts of Rb in prostates from Pten and Zbtb7a double-null mice coincided with the upregulation of a panel of proven E2f1 transcriptional target genes ( Supplementary Table 5 ), although it has been shown recently that the regulation of senescence by Rb in mouse prostate is at least partly independent of E2f protein function 48 . Although the Rb-E2f pathway was clearly affected in prostate cancer with loss of both Pten and Zbtb7a, we cannot rule out the possibility that loss of Zbtb7a may also affect PICS by perturbing additional, unknown pathways that promote senescence.
Taken together, these results show that, during prostate tumorigenesis, the oncosuppressive function of Zbtb7a directly impinges on the oncogenic activity of Sox9 and that Zbtb7a loss in the prostate favors (i) senescence bypass, (ii) increased proliferation rate, (iii) resistance to apoptosis and (iv) greater invasive potential.
Loss of ZBTB7A expression in human prostate cancer
We next investigated the status of ZBTB7A in human prostate cancer by first analyzing the expression of ZBTB7A mRNA and protein, respectively, in the Oncomine database and a customized human prostate cancer tissue microarray (TMA) (see also ref. 49 ). In line with our mouse data, our analysis of prostate cancer expression profile data sets [50] [51] [52] [53] [54] showed that ZBTB7A was underexpressed in prostate cancer and downregulated upon tumor progression to high Gleason score and metastasis (Fig. 4a-d and Supplementary Fig. 5 ; see also ref. 49) . Additionally, we analyzed human prostate cancer expression array data from men with prostate cancer stratified by prostate cancer recurrence 55 (Fig. 4d) , finding that ZBTB7A transcript levels were significantly lower in tumors demonstrating greater propensity for recurrence ( Fig. 4d) . As the ZBTB7A transcript is extremely GC rich (70%), which may affect specificity in annealing to the probe, we analyzed multiple prostate cancer expression profile data sets (11 in total) [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] ; of these, 6 clearly showed downregulation of ZBTB7A in human prostate cancer and metastases, whereas 3 did not permit npg A r t i c l e s any clear conclusion, and 2 showed no significant change in the expression of ZBTB7A in prostate tumors relative to normal samples (details on all the interrogated data sets and the criteria followed for the analysis are given in Supplementary Table 6 ).
To further define the cause of ZBTB7A loss in human cancer, we employed a multifaceted approach. Notably, array-comparative genomic hybridization (aCGH) analysis for genetic alterations involving the region of ZBTB7A on chromosome 19 showed that 18% of individuals with advanced prostate cancer (10 of 55) harbored monoallelic loss of ZBTB7A (Supplementary Fig. 6a ; see also ref. 49 ). Additionally, we recently found that ZBTB7A levels are strongly downregulated by the miR-17 family (including miR-20a, miR-93 and miR-106b 61 ; Supplementary  Fig. 6b-e ), which regulates ZBTB7A mRNA translation more than transcript degradation 61 and also targets PTEN 62 . The MIR106B~25 cluster is located in intron 13 of the MCM7 gene (encoding minichromosome maintenance complex component 7), one of the most genetically amplified loci in human advanced prostate cancer 63 . Accordingly, we found this miRNA family markedly upregulated in human prostate cancer (Fig. 4e) 53 , and immunohistochemistry analysis with antibody to ZBTB7A of a TMA that included 50 human samples of primary prostate cancer (detailed information given in Supplementary Table 7 ) confirmed loss of ZBTB7A protein in approximately 50% (22/42) of the biopsied specimens analyzed ( Fig. 4f; 8 out of 50 prostate cancer samples were excluded from the analysis for technical reasons). Notably, we also observed significant association between ZBTB7A and PTEN protein loss in these 42 prostate cancer specimens (χ 2 test P = 0.0123) ( Fig. 4g) , further suggesting cooperative oncosuppressive roles for ZBTB7A and PTEN in human prostate cancer (see also ref. 49 ). Lastly, we performed immunohistochemistry analysis of ZBTB7A and SOX9 on the same TMA and found that 20 out of 36 human advanced prostate tumors (with Gleason scores of 8-10) (detailed information given in Supplementary Table 7 ) were characterized by high levels of SOX9 expression ( Supplementary Fig. 7a,b) . Notably, 12 of these 20 tumors also had concomitant loss of ZBTB7A protein (Supplementary Fig. 7a,b) .
DISCUSSION
In this work, we have unexpectedly demonstrated that loss of Zbtb7a accelerates the progression of Pten loss-driven tumors in the prostate. This notion is further corroborated by the lack of tumorigenesis and any discernible abnormal phenotype in mice that overexpressed ZBTB7A specifically in the prostate epithelium (Pbsn-ZBTB7A transgenic lines; Supplementary Fig. 1) . ZBTB7A therefore has an important role in tumorigenesis, not only when overexpressed but also when downregulated, depending on its cellular and genetic milieu. In mechanistic terms, we show that Zbtb7a loss greatly accelerates the progression of Pten loss-driven prostate tumors by strongly activating the oncogenic transcriptional activity of Sox9, a key step that in prostate cancer leads to bypass of PICS and the activation of Sox9-dependent transcriptional signatures that promote proliferation, survival and invasion (Fig. 4h) .
Notably, we determined that ZBTB7A is also genetically lost and transcriptionally and post-transcriptionally downregulated in human prostate cancers and that loss of ZBTB7A protein strongly correlates with loss of PTEN protein in advanced prostate cancer. We showed that ZBTB7A and PTEN transcripts are both targets of miRNAs encoded by the MIR106B~25 cluster located in intron 13 of MCM7 (ref. 62) . MCM7 is one of the most amplified oncogenes in human prostate cancer, and its expression is highly correlated with tumor progression, biochemical recurrence and distant metastases 63 npg been identified as frequent events in human prostate cancer [65] [66] [67] [68] [69] and are strongly associated with loss of PTEN. Robust evidence of functional cooperation between these genetic lesions has been provided by a plethora of different studies, particularly by those using specific mouse models 15, 70, 71 . Given that loss or downregulation of ZBTB7A is also associated with PTEN loss in advanced prostate tumors, it is conceivable that ZBTB7A might have important oncosuppressive functions in the context of TMPRSS2-ERG fusion or TP53 loss or mutation in counteracting the progression of prostate tumors as well as the response to specific treatments 49 . Thus, genetic analysis in mouse models has identified an unpredicted dual role of ZBTB7A in oncogenesis through its ability to control major tumor pathways such as ARF-p53, RB and SOX9, in a context-and tissue-dependent manner and has defined a new oncogenic pathway triggered by ZBTB7A loss that is pathogenetically linked to the amplification of the MCM7 locus in advanced human prostate cancer.
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